Join Professor Otavio Berwanger, Executive Director for The George Institute for Global Health, UK and Chair in Clinical Trials at Imperial College London for his inaugural lecture online or in person.
There is no need to register to attend so please be sure to use the add to calendar button.
We look forward to welcoming you on Wednesday 5 March!
Summary
Randomised clinical trials (RCTs) represent the gold standard for determining whether a healthcare intervention reduces the risk of patient-important outcomes. Traditionally, RCTs take place in highly controlled environments, which may not reflect real-world conditions. In this sense, despite its potential to inform clinical practice, traditional RCT models have their drawbacks, including elevated costs, long completion times, failure to recruit the target sample sizes, lack of diversity, and complex operational procedures. Therefore, improving the participants’ experience and trials’ overall efficiency constitutes an important unmet need.
Innovative and efficient pragmatic large-scale clinical trial models address the limitations of traditional trials by increasing relevance, improving speed and cost-efficiency, and enhancing patient-centeredness and inclusivity. They play a critical role in advancing medical research and accelerating the adoption of evidence-based practices in real-world settings.
Professor Otavio Berwanger is Executive Director for The George Institute for Global Health, UK and Chair in Clinical Trials at Imperial College London. In his inaugural lecture, Professor Berwanger will explore topics like novel trial designs (such as platform and adaptive trials), use of routinely collected data to improve trial efficiency, decentralized clinical trial models and use of digital technologies and patient and consumer engagement in trial design and conduct.
Biography
Professor Otavio Berwanger is Executive Director for The George Institute for Global Health, UK and Chair in Clinical Trials at Imperial College London. An esteemed cardiologist and clinical trialist, Otavio has extensive research and managerial experience and has led large-scale, global randomised clinical trials. Studies led by Otavio have been published in high-impact journals such as the New England Journal of Medicine, Lancet, JAMA and BMJ. In his capacity as Executive Director he leads the Institute’s work in partnership with Imperial College London, with its core focus on large-scale clinical trials, health systems science, multimorbidity, and women’s health He will also build on his personal research interests in exploring innovative and efficient patient-centric clinical trial models.
